Intralymphatic Immunotherapy in Increasing Doses, Substudy

NCT02975479 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Rhinitis, Allergic, Seasonal

Interventions

DRUG: ALK Diluent
DRUG: ALK Alutard SQ 5-grasses or ALK Alutard Birch

Sponsor

Karolinska Institutet

Collaborators

[object Object]
[object Object]